Humanigen, Inc. Their focus is on preventing and treating a condition called 'cytokine storm', which is an immune hyper-response. They have developed a first-in-class antibody called lenzilumab that specifically targets and neutralizes a protein called granulocyte-macrophage colony-stimulating factor (GM-CSF).

GM-CSF is known to regulate various inflammatory cytokines and chemokines involved in cytokine storm. Humanigen's Phase 3 LIVE-AIR study has shown promising results, suggesting that early intervention with lenzilumab could prevent the severe consequences of a cytokine storm in hospitalized COVID-19 patients. Additionally, they are exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease, eosinophilic asthma, and rheumatoid arthritis.

Lenzilumab is also being studied as a potential treatment for cytokine storm associated with CD19-targeted CAR-T cell therapies. The company is dedicated to advancing medical science and improving patient outcomes. For more information on Humanigen and their breakthrough treatments, you can visit their website and browse their informative videos, publications, and contact resources